Silexion Therapeutics Corp.SLXN
Key ratios
ROA
-144.3%2025
2024
-193.5%
Recent news
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
Track SLXN in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer